Literature DB >> 16823912

Bacterial derived proteoliposome as ideal delivery system and cellular adjuvant.

Tamara Rodríguez1, Oliver a Pérez, Sanja Ugrinovic, Gustavo Bracho, Pietro Mastroeni.   

Abstract

We explored the potential of a proteoliposome (PL) from the outer membrane of N. meningitidis B, as an immunopotentiator and as a vector for antigen delivery to dendritic cells (DC). DC were incubated with PL resulting in up-regulation of MHC-II, CD40, CD80, and CD86 expression and production of TNFalpha and IL12(p70). Ovoalbumin (OVA) was incorporated within PL (PL-OVA). PL-OVA presented OVA-specific peptides to CD4+ and CD8+ OVA-specific T-cell hybridomas. PL exerts an immunomodulatory effect on DC and is a general system to deliver antigens for presentation to CD4+ and CD8+ T-cells possibly implicated in the induction CD8+ cytotoxic T lymphocytes (CTLs) responses.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16823912     DOI： 10.1016/j.vaccine.2005.01.106

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Bacterial outer membrane vesicles and vaccine applications.

Authors:  Reinaldo Acevedo; Sonsire Fernández; Caridad Zayas; Armando Acosta; Maria Elena Sarmiento; Valerie A Ferro; Einar Rosenqvist; Concepcion Campa; Daniel Cardoso; Luis Garcia; Jose Luis Perez
Journal:  Front Immunol       Date:  2014-03-24       Impact factor: 7.561

2.  Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes.

Authors:  Nya L Fraleigh; Reynaldo Oliva; Jordan D Lewicky; Alexandrine L Martel; Reinaldo Acevedo; García-Rivera Dagmar; Hoang-Thanh Le
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

3.  New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity.

Authors:  Beatriz Tamargo; Yanet Márquez; Wendy Ramírez; Bárbara Cedré; Manuel Fresno; Gustavo Sierra
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

4.  Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1).

Authors:  Nya L Fraleigh; Justin Boudreau; Nitin Bhardwaj; Nelson F Eng; Yanal Murad; Robert Lafrenie; Reinaldo Acevedo; Reynaldo Oliva; Francisco Diaz-Mitoma; Hoang-Thanh Le
Journal:  Heliyon       Date:  2016-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.